Pan-cancer analysis shows that MAMDC2 is significantly downregulated in 15 malignancies, including urothelial carcinoma, invasive breast cancer, cervical cancer, and endometrial cancer. This evidence concerns the gene MAMDC2 and invasive breast carcinoma.